Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Phio Pharmaceuticals : Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021

08/31/2021 | 08:06am EDT

MARLBOROUGH, Mass., Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Details are as follows:

Event:

ESMO Virtual Congress 2021

Title:

Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors 

Authors: 

Benjamin Cuiffo, et al.

Abstract Number:

#4154

Date:

September 16-21, 2021

An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website (click here).

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the  future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com 

Investor Contact
Ashley R. Robinson 
LifeSci Advisors
arr@lifesciadvisors.com

Cision
View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-data-presentation-at-the-esmo-virtual-congress-2021-301365371.html

SOURCE Phio Pharmaceuticals Corp.


© PRNewswire 2021
All news about PHIO PHARMACEUTICALS CORP.
10/18PHIO PHARMACEUTICALS : Announces Upcoming Presentation at the SITC 36th Annual Meeting
PR
10/07PHIO PHARMACEUTICALS : Presents New BRD4 Data at the AACR-NCI-EORTC International Conferen..
PR
09/30PHIO PHARMACEUTICALS : Announces Two Upcoming Data Presentations at Scientific Conferences..
PR
09/16US Stocks Mostly Lower Thursday After Surprise Retail Sales Gain, Rise in Jobless Claim..
MT
09/16US Stocks End Mostly Lower as Investors Weigh Surprise Retail Sales Gain Against Rising..
MT
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Muted in Premarket Thursday
MT
09/16PHIO PHARMACEUTICALS : Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immu..
PR
09/16Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Imm..
CI
09/10PHIO PHARMACEUTICALS : HCW 23rd Annual Global Investment Conference Presentation
PU
More news
Analyst Recommendations on PHIO PHARMACEUTICALS CORP.
More recommendations